You are cordially invited to Oppenheimer’s


Featuring Chemistry of Life Processes Institute
at Northwestern University

Northwestern University

Wednesday, March 27, 2019
7:45AM – 5:30PM

Northwestern University
Kellogg School of Management
Global Hub, White Auditorium
2211 Campus Dr., Evanston, IL

Breakfast, lunch and cocktail reception will be served. We will provide free parking vouchers for the North Parking Garage at 2311 N. Campus Drive and Segal Visitor’s Center Garage at 1841 Sheridan Rd.

View Agenda



Please join us on March 27, 2019 for the Oppenheimer ‘Biotech Summit by the Lake’ featuring Northwestern University's Chemistry of Life Processes Institute.

The day will feature a series of presentations on topics in biotechnology and drug development by leading Northwestern faculty innovators and management of major biotech companies with ties to Northwestern.

The event is free by invitation only. Advanced registration is required as space is limited.

Oppenheimer Northwestern University



Jay Walsh, PhD
Vice President for Research, Northwestern University


Thomas V. O’Halloran, PhD
Founding Director, Chemistry of Life Processes Institute
Charles E. And Emma H. Morrison Professor,
Departments of Chemistry and Molecular Biosciences, Weinberg College of Arts and Sciences, Professor of Medicine, Feinberg School of Medicine


Vadim Backman, PhD
Walter Dill Scott Professor of Biomedical Engineering,
McCormick School of Engineering; Professor,
Biochemistry and Molecular Genetics and Medicine,
Feinberg School of Medicine
“Developing novel strategies for chromatin regulation to fight resistance in cancer chemotherapy“

Susan E. Quaggin, MD
Charles H. Mayo, MD, Professor of Medicine;
Director, Feinberg Cardiovascular and Renal Research Institute;
Chief, Nephrology and Hypertension,
Department of Medicine, Feinberg School of Medicine
“A High 'TEK' Solution for Vascular Diseases”

Richard B. Silverman, PhD
Patrick G. Ryan/Aon Professor
Professor of Chemistry and Professor of Molecular Biosciences,
Weinberg College of Arts and Sciences
“Hepatocellular Carcinoma and ALS: Serious Unmet Medical Diseases Being Addressed in the Silverman Group”

Evan Scott, PhD
Assistant Professor of Biomedical Engineering;
McCormick School of Engineering
“A Scalable Platform for Enhanced Delivery and Efficacy of Diverse Therapeutic and Diagnostic Agents”

Douglas E. Vaughan, MD
Chair, Department of Medicine;
Irving S. Cutter Professor of Medicine;
Professor of Medicine (Cardiology),
Feinberg School of Medicine
“Targeting PAI-1: A Novel Approach to Delay the Multi-morbidity of Aging”

Teresa K. Woodruff, PhD
Thomas J. Watkins Professor of Obstetrics and Gynecology
and Dean, The Graduate School
“Oncofertility: From Bench to Bedside to Babies”



Jay Olson, CFA
Research Analyst
Oppenheimer & Co.

Silvan Tuerkcan, PhD
Oppenheimer & Co.


Margarita Chavez, JD
Managing Director
AbbVie Ventures (ABBV)

Michael Margolis, RPh
Managing Director
Oppenheimer & Co.

Jim Sullivan, PhD
Venture Partner

S. Edward Torres
Founder and Managing Director
Lilly Ventures


Brian Bernick, M.D., F.A.C.O.G. (WCAS'91)
Co-Founder and Director
TherapeuticsMD (TXMD)

Andrew Chan, MD, PhD (WCAS'80)
Senior Vice President, Research Biology
Genentech (RHHBY)

Tassos E. Gianakakos (TGS'96)
Chief Executive Officer
MyoKardia (MYOK)

Ankit Mahadevia, MD (WCAS’01)
President and CEO
Spero Therapeutics (SPRO)

Chandler D. Robinson, MD (WCAS'06)
Co-Founder and Chief Executive Officer
Monopar Therapeutics

Sujal A. Shah (McC'95 McC'97)
President and Chief Executive Officer
CymaBay (CBAY)

Terms of use: Copyright © 2018 Oppenheimer & Co. Inc.
Business on All Principal Exchanges and
Member SIPC.